AMN1: A Drug Target / Disease Biomarker (G196394)

Target Name: AMN1

NCBI ID: G196394

AMN1

AMN1: A Drug Target / Disease Biomarker

AMN1 (Alzheimer's Disease Neurostrain-1) is a protein that is expressed in the brain and has been linked to the development and progression of Alzheimer's disease (AD). It is a potential drug target (or biomarker) for the treatment of AD and has been the focus of research in the field of neurodegenerative diseases.

AMN1 is a transmembrane protein that is expressed in the brain and has been shown to be involved in the regulation of several important cellular processes, including inflammation, neurotransmitter signaling, and cell survival. It is a key player in the formation of neurofibrillary tangles, a hallmark of AD, and has been shown to contribute to the development and progression of the disease.

One of the main challenges in the treatment of AD is the development of resistance to therapeutic interventions, which is often a result of the formation of neurofibrillary tangles. AMN1 has been shown to be involved in the formation of these tangles and has been shown to contribute to the development of neurofibrillary tangles in both humans and animal models of AD.

In addition to its role in the development of neurofibrillary tangles, AMN1 has also been shown to be involved in the regulation of several important signaling pathways that are involved in the development and progression of AD. For example, AMN1 has been shown to be involved in the regulation of the TGF-β pathway, a pathway that is involved in the development of neurofibrillary tangles and the formation of neurofibrillary islands.

AMN1 has also been shown to be involved in the regulation of the NF-kappa-B pathway, a pathway that is involved in inflammation and neurodegeneration. The NF-kappa-B pathway is often disrupted in AD and has been implicated in the development and progression of the disease. AMN1 has been shown to play a role in the regulation of NF-kappa-B signaling and has been shown to contribute to the development of neurofibrillary tangles in AD.

In conclusion, AMN1 is a protein that has been shown to be involved in the development and progression of Alzheimer's disease. Its role in the regulation of cellular processes and its involvement in the formation of neurofibrillary tangles make it a potential drug target (or biomarker) for the treatment of AD. Further research is needed to fully understand the role of AMN1 in the development and progression of AD and to develop effective therapies that target this protein.

Protein Name: Antagonist Of Mitotic Exit Network 1 Homolog

The "AMN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets